Chemotherapy Induced Nausea and Vomiting (CINV) Market Poised for Strong CAGR of 8.32% until 2023


Published on : Apr 28, 2017

Albany, New York, April 28, 2017: Chemotherapy induced nausea and vomiting are the worst feared side effects for the person dealing with chemotherapy treatment. The growing number of cancer patients, increased use of chemotherapy as a treatment, and more use of chemotherapeutic drugs has anticipated for the growth of CINV market. The market insight is totally analyzed by a new study added in the repository of Market Research Hub (MRH) and titled as “Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023”. The report has thoroughly analyzed and reveals a forecasted growth of market with a CAGR of 8.32% for the time period until 2023.

CINV is a medical condition that makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear of future nausea and vomiting. Due to these side effects, the patients can’t get the nutrition properly and lose their energy and may become weak which may delay the further chemotherapy cycles as the patient wouldn’t be physically strong to bear the chemotherapy side-effects. To repulse the side effects and for the patients to continue the treatment without any fear, there are many CINV drugs available in the market which are owing to the market growth of CINV, that is projected to grow immensely in coming years also.

It has also been analyzed that, several classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients.

The report starts with the chemotherapy induced nausea and vomiting market overview, followed by the deep analysis of the global market size of CINV for 2016 and 2023. Further, CINV type, risk factors, pathophysiology of CINV, epidemiology and patient population is evaluated and listed for detailed analysis.

In the next section, a summary of anti-emetics prescribing is provided that includes first line anti-emetics, second line anti-emetics and standard anti-emetic regimes for haematology oncology. Further, the marketed drugs are listed which are used for the treatment. Marketed drugs presently available in the market are:

  • Sustol: Heron Therapeutics
  • Sancuso: Kyowa Kirin Inc
  • Aloxi: Helsinn Birex Pharmaceuticals Ltd.
  • Akynzeo: Helsinn Birex Pharmaceuticals Ltd.
  • Emend: Merck Sharp and Dohme Ltd
  • Varubi: Tesaro Inc.
  • Ivemend: Merck Sharp & Dohme Ltd
  • Kytril: Hoffmann-La Roche
  • Syndros: Insys Therapeutics

Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1063534

Moreover, the report is completed by providing a complete overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) in the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. This research report concludes with the key market drivers, market barriers and unmet needs of the CINV market for precise market understanding which is helpful for the new market participants.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top